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A B S T R A C T
Prostaglandin E2 (PGE2) is a ligand of the E-type prostanoid receptors, EP1-4. PGE2 secretion is increased in the
airways of patients with asthma by secretory phospholipases A2, which also increases MUC5AC mucin in goblet
cells. We hypothesized that PGE2 would also increase MUC5AC mRNA and secreted protein through speciﬁc EP
receptor activation. We sought to assess the eﬀect of speciﬁc EP receptor activation on MUC5AC secretion from
ciliated-enriched cells or goblet-enriched cells induced by IL-13. We develop an enriched goblet cell epithelium
by growing normal human bronchial epithelial cells at air liquid interface for 14 days in the presence of IL-13.
We examined exposure to 4 speciﬁc EP receptor agonists at 24 h and 14 days in cells grown with or without IL-13
exposure, and measured MUC5AC mRNA and secreted protein, as well as airway culture morphology, and EP
receptor expression. In ciliated-enriched cells grown in the absence of IL-13, the EP4 receptor agonist modestly
increased both MUC5AC mRNA and secretion (p < 0.001, 241% increase of transcripts and p < 0.01, 86%
increase of secreted protein) but did not visibly change cell morphology. In goblet-enriched cells grown in the
presence of IL-13, the EP4 receptor agonist greatly increased both MUC5AC mRNA and protein (p < 0.001,
315% increase of transcripts and 92% increase of secreted protein). Speciﬁc activation of the other EP receptor
had no eﬀect on secreted mucin. EP4 receptor mRNA and protein were signiﬁcantly increased in goblet-enriched
cells, while the other receptor mRNA were decreased. We conclude that PGE2 stimulates airway mucin pro-
duction predominantly by EP4 receptor activation in association with increased EP4 receptor expression. This
may contribute to mucus hypersecretion as seen in severe asthma.
1. Introduction
Asthma is characterized by airway eosinophilia, goblet cell hyper-
plasia with mucus hypersecretion, and airway hyperresponsiveness [1].
In particular, mucus hypersecretion is related to small airway ob-
struction and mortality in severe asthma [2]. MUC5AC, the principal
gel-forming mucin in airway, is primarily expressed in goblet cells and
asthmatic patients produce MUC5AC-rich mucus [3,4]. The T2 cyto-
kine, IL-13, drives primary airway cells towards a goblet cell phenotype
[5,6].
Prostaglandin E2 (PGE2) is a cyclooxygenase metabolite of arachi-
donic acid and has pleiotropic eﬀects on airway structure and function.
The most abundant sources of PGE2 are epithelial cells, ﬁbroblasts, and
macrophages [7]. PGE2 concentration is increased in sputum from
subjects with asthma [8]. PGE2 acts through four distinct E-type
prostanoid receptors that are expressed in the airway, EP1- 4 [7,9].
Among these four G protein-coupled receptors, EP2 and EP4 receptor
activation produces bronchodilation and anti-inﬂammatory eﬀects in
human and rodent airway smooth muscle cells and macrophages
[10–12]. In contrast, EP3 receptor activation contributes to cough by
activating airway sensory nerves [13].
The EP2/EP4 receptor dual agonist, misoprostol can increase
MUC5AC protein production in cultured human airway epithelial cells
[14]. PGE2 is produced by secretory phospholipases A2 (sPLA2) in-
itiating the cyclooxygenase pathway, and stimulates mucus secretion
[15,16]. We have shown that sPLA2 are secreted from the ciliated cells
and can dramatically induced mucus secretion from IL-13 transformed
goblet cells [17]. We hypothesized that PGE2 would stimulate cultured
airway cells towards goblet cell metaplasia via speciﬁc EP receptor
activation and that mucin production by EP receptor activation would
be enhanced in goblet cells.
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2. Materials and methods
2.1. Reagents
The following reagents were purchased: recombinant human IL-13
(R&D Systems, Minneapolis, MN, USA.); DMEM, Ham's F12 medium
(Gibco, Grand Island, NY, USA); bronchial epithelial cell growth
medium, SingleQuotR® kit and Hanks' balanced salt solution (HBSS)
(Lonza Walkersville Inc., Walkersville, MD, USA); dimethyl sulphoxide
(DMSO) and indomethacin (Sigma-Aldrich Co., St. Louis, MO, USA).
The EP1 receptor agonist: ONO-DI-004, EP2 receptor agonist: ONO-
AE1-259, EP3 receptor agonist: ONO-AE-248, and EP4 receptor agonist:
ONO-AE1-329 were kindly supplied by ONO pharmaceutical company
(Osaka, Japan).
2.2. Normal human bronchial epithelial (NHBE) cell culture
NHBE cells (Lonza Walkersville Inc.) were cultured and diﬀer-
entiated at air-liquid interface as previously described [5,17]. The
NHBE cells were from healthy subjects without lung disease or history
of smoking. NHBE cells were seeded at 3500 cells/cm2 and grown in
bronchial epithelial cell growth medium supplemented with the Sin-
gleQuotR® kit at 37 °C with 5% CO2. The medium was changed every
48 h, and the cells were cultured until 70–80% conﬂuence. At the
second passage, the cells were seeded to polyester membrane transwell-
clear inserts of 0.4 μm pore size, 6.5 mm diameter, 10 μm thickness
(Corning, Lowell, MA, USA) at 2.0 × 105 cells/cm2. NHBE cells were
then cultured in DMEM/Ham's F12 medium with 1% insulin-trans-
ferrin-selenium A, recombinant epidermal growth factor (0.5 ng/mL),
triiodothyronine (10 ng/mL), hydrocortisone (0.5 μg/mL), all-trans
retinoic acid (1.0 × 10−7 M), BSA (2.0 μg/mL) and bovine pituitary
extract (30 μg/mL). After achieving 70–80% conﬂuence, the apical side
of the medium was removed and cells were cultured at an ALI. The
medium was changed every 48 h at 37 °C with 5% CO2 and the cells
were further cultured for 14 days. All experiments were performed with
cells from these 3 donors with 2 or 3 replicate experiments as indicated.
2.3. IL-13 and EP receptor agonist exposure
NHBE cells were grown for 14 days with IL-13 at 0, 1, 5, or 10 ng/
mL in the basal medium that was changed every 48 h in order to
evaluate the eﬀect of IL-13 on cell morphology, MUC5AC and PGE2
production (supplemental method and ﬁgure). To assess the eﬀect of EP
receptor activation, NHBE cells were grown at ALI for 14 days in the
presence of 0 or 5 ng/mL IL-13 and 1000 nM of indomethacin, a non-
selective COX inhibitor (to prevent the production and release of en-
dogenous PGE2) while exposed to selective EP receptor agonists. At day
13, NHBE cells were exposed at the basal or apical side to the EP1, EP2,
EP3, and EP4 receptor agonist to assess mRNA and protein. A 14 day
exposure to each EP agonist at the basal side was used to evaluate
mucin protein by ELISA and by the histology of the cultured cells. At
day 14, cell lysate was collected for quantitative RT-PCR and Western
blotting. Cell supernatants were also collected for ELISA. DMSO was
used as the vehicle for the EP1, EP3, and EP4 receptor agonist. Deio-
nized water was used as the vehicle for the EP2 receptor agonist ac-
cording to supplier's recommendation. The EP receptor agonists were
diluted to 10 mM, then diluted to target concentration in the culture
medium. Cell viability was evaluated by WST-8 assay (Cell Counting
Kit-8, Dojindo, Kumamoto, Japan).
2.4. Real-time quantitative PCR
At day 14, the apical side of the cells was washed three times with
PBS, and total RNA was extracted using the Aurum™ Total RNA Mini Kit
(Bio-Rad Laboratories Inc., Hercules, CA). Total RNA was used to syn-
thesize the ﬁrst-strand cDNA (Script TM cDNA synthesis kit; Quanta
BioSciences, Inc., Gaithersburg, MD, USA). Quantitative PCR was per-
formed on the C1000TM thermal cycler equipped with CFX96TM real-
time PCR system (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Perfecta SYBR Green (Quanta BioSciences, Inc.) was used as a DNA
intercalator dye to monitor ampliﬁed DNA quantiﬁcation, and real-time
quantitative PCR curves were analyzed by CFX Manager software (Bio-
Rad Laboratories Inc.) to obtain threshold cycle values for each sample.
For the relative quantiﬁcation of MUC5AC and EP receptor mRNA ex-
pression, the expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) served as a housekeeping control. The following primers were
used [5,14,18]:
MUC5AC forward: 5′-TACTCCACAGACTGCACCAACTG-3′,
MUC5AC reverse: 5′-CGTGTATTGCTTCCCGTCAA-3′,
EP1 receptor forward: 5-ATGGTGGGCCAGCTTGTC-3
EP1 receptor reverse: 5-GCCACCAACACCAGCATTG-3
EP2 receptor forward: 5-GCCTGCAACTTCAGTGTCATTC-3
EP2 receptor reverse: 5-GTCCGCAGCGGCTTCT -3
EP3 receptor forward: 5-GACGGCCATTCAGCTTATGG -3
EP3 receptor reverse: 5-CTGATTGAAGATCATTTTCAACATCA-3
EP4 receptor forward: 5-ACATGTACGCGGGCTTCAG-3
EP4 receptor reverse: 5-GCCGCACACAAGCACGTT-3
GAPDH forward 5′-TGAACGGGAAGCCACGG-3′,
GAPDH reverse 5′-TCCACCACCCTGTTGCTGTA-3’.
2.5. ELISA for MUC5AC in cells supernatants
Apically secreted MUC5AC protein was measured by ELISA [5,17].
Culture supernatants were collected by adding 250 μL of HBSS to the
apical side of the inserts at day 14. The 96-well plate was coated with
50 μL supernatant sample and bicarbonate-carbonate buﬀer (50 μL) and
were incubated at 37 °C overnight until samples dried. After washing
with 2% BSA/PBS containing 0.05% Tween20 was added to each well
and incubated at room temperature for 1 h as blocking. After washing,
anti-MUC5AC antibody (45M1; Thermo Scientiﬁc, Waltham, MA, USA)
was added and the plate was incubated for 2 h at room temperature.
Anti-mouse immunoglobulin, horseradish peroxidase-linked whole an-
tibody (GE Healthcare, Pittsburg, PA, USA) for MUC5AC was added,
and the plate was incubated for 1 h at room temperature and, 3,3 9,5,5
9 -tetramethylbenzine peroxidase solution was then added, and the
plate was incubated at room temperature. The reaction was stopped
with H2SO4 and the absorbance was measured at 450 nm with the
ELx808 Ultra Microplate Reader (Bio Tek Instruments, Inc., Winooski,
VT, USA). Data are expressed as the percentage above the PBS control.
2.6. Western blot analysis for cell signaling and EP4 receptor
Cells were cultured in supplement-free medium for 48 h before EP
agonist exposure at 1000 nM, to avoid the inﬂuence of growth factors
on cell signaling. The cell lysates were harvested 0, 5, 15 30, 60, and
120 min after the EP4 agonist exposure. Cells were washed with cold
PBS, and lysed on ice in a modiﬁed ratio immunoprecipitation buﬀer
Abbreviations
ALI air liquid interface
GAPDH glyceraldehyde-3-phosphate dehydrogenase
NHBE cells normal human bronchial epithelial cells
PAS periodic acid-Schiﬀ
PGE2 Prostaglandin E2
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electro-
phoresis
SEM standard error of the mean
sPLA2 secretory phospholipases A2
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(1% Nonidet P-40, 1% sodium deoxycholate, 150 mM NaCl, 10 mM Tris
pH 7.5, 5 mM sodium pyrophosphate, 1 mM NaVO4, 5 mM NaF, 1 μg/
mL aprotinin, 1 μg/mL leupeptin, and 0.1 mM phenylmethylsulfonyl
ﬂuoride) for 15 min and scraped from the plates. DNA was collected by
passing the lysate, and insoluble material was removed by centrifuga-
tion at 20,000 × g for 15 min at 4 °C. The protein concentration of the
supernatants was quantiﬁed using the Detergent Compatible Protein
Assay (Bio-Rad Laboratories Inc.). Equal amounts of protein extracts
were loaded on a 12% SDS-PAGE mini gel and transferred to a ni-
trocellulose membrane (Bio-Rad Laboratories Inc.) by Trans-Blot®
Turbo™ Transfer system (Bio-Rad Laboratories Inc.). Membranes were
rinsed with distilled water, incubated for 1 h in Tris-buﬀered saline
(0.8% NaCl and 20 mM Tris pH 7.6) that contained 0.1% Tween 20
(TBS-T) and 5% BSA to block nonspeciﬁc interactions. After blocking,
the membranes were incubated overnight at 4 °C with primary anti-
bodies: phospho-CREB and CREB diluted 1:1000 (Cell Signaling
Technology, Danvers, MA, USA), EP4 receptor diluted 1:100 (sc-55596;
Santa Cruz Biotechnology, Dallas, TX, USA), or β-actin diluted 1:5000
(A5441; Sigma-Aldrich). The membranes were then incubated for 1 h
with anti-rabbit IgG HRP secondary antibody diluted 1:2000 (Cell
Signaling Technology) or anti-mouse IgG HRP secondary antibody di-
luted 1:5000 (GE Healthcare), respectively and detected using ECL
detection reagent (GE Healthcare). Western blot images were scanned
and analyzed using NIH Image J software (https://imagej.nih.gov/ij/).
2.7. Histology
Cell morphology was evaluated after hematoxylin-eosin (H&E),
periodic acid-Schiﬀ (PAS), and MUC5AC staining. For MUC5AC
staining, EnVisionTM 1 Dual Link System-HRP (Dako, North America
Inc., Carpinteria, CA) was added as the second antibody. Antigen-an-
tibody complexes were visualized using the Liquid DAB 1 Substrate
Chromogen System (Dako, North America Inc.). The transwell
membrane with cells was ﬁxed in neutral 20% formalin, embedded in
paraﬃn, and then cut into 8 μm slices. The cell morphology was as-
sessed with a light microscope (CKX41; Olympus, Tokyo, Japan) and
photographed using a digital camera system (AxioCam ICc 1; Carl Zeiss,
Thornwood, NY).
2.8. Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM).
Comparisons between the two groups were made by Mann-Whitney U
test. Multiple comparisons were examined by Kruskal-Wallis test as
appropriate. A post hoc analysis for multiplicity was performed by using
Dunn's multiple comparison test. Conventionally, P value less than 0.05
was considered statistically signiﬁcant. Statistical analysis was per-
formed using JMP Pro 12 for Mac (SAS, Cary, NC, USA).
3. Results
3.1. Eﬀect of IL-13 on MUC5AC mRNA expression and secreted protein,
PGE2 secretion, and cell diﬀerentiation
After 14 days, IL-13 dose dependently increased PGE2 secretion, but
MUC5AC mRNA and secreted protein increase peaked at an IL-13
concentration of 5 ng/mL [17] (Supplement Fig. 1A, B, C). While 1 ng/
mL of IL-13 showed a small eﬀect on goblet cell diﬀerentiation, 5 ng/
mL and 10 ng/mL of IL-13 transformed cells into highly enriched goblet
cell morphology (Supplement Fig. 1D).
3.2. Eﬀect of short-term (24 h) exposure to PGE2 receptor agonists on
MUC5AC mRNA and secreted protein
Exposure to the EP4 receptor agonist for 24 h increased MUC5AC
mRNA in both ciliated-enriched and goblet-enriched cells (p < 0.001,
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Fig. 1. The eﬀect of PGE receptor agonists on MUC5AC mRNA
expression.
(A) Apical EP2 receptor activation, and EP4 agonist at the apical or
basal side increased MUC5AC mRNA in ciliated-enriched cells. (B)
Apical or basal EP4 receptor activation increased MUC5AC mRNA
expression in goblet-enriched cells.
Concentration of each EP receptor agonist was 1000 nM. Results are
given as mean ± SEM from 3 diﬀerent donors with 3 technical
replicates. The fold change is relative to no EP receptor agonist for
ciliated-enriched cells. Signiﬁcant is indicated by **p < 0.001
between ciliated-enriched cells control and the EP4 receptor agonist
(Kruskal-Wallis test followed by Dunn's multiple comparison test);
##p < 0.001 between goblet-enriched cells control and the EP4
receptor agonist (Kruskal-Wallis test followed by Dunn's multiple
comparison test).
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241% increase and 313% increase respectively at 1000 nM, basal ex-
posure) (Fig. 1A and B). Both apical and basal exposure to the EP4
receptor agonist increased MUC5AC mRNA. Although exposure to the
EP2 receptor agonist at the apical side increased MUC5AC mRNA in
ciliated-enriched cells, it had no eﬀect on goblet-enriched cells. The EP1
and EP3 receptor agonist had no eﬀect on MUC5AC mRNA. There was
no eﬀect on MUC5AC secreted protein in either ciliated-enriched cells
or goblet-enriched cells with 24 h exposure to any of the EP receptor
agonists (Supplemental Fig. 2). The EP receptor agonists at 1000 nM for
24 h or 14 days exposure had no eﬀect on cell viability.
3.3. Eﬀects of long-term (14 days) exposure to PGE2 receptor agonists on
MUC5AC secreted protein
The EP4 receptor agonist modestly increased MUC5AC protein in
ciliated-enriched cells (p < 0.01, 86% increase at 1000 nM) (Fig. 2A).
However, cells exposed to the EP4 receptor agonist at 0 or 1000 nM for
14 days were morphologically indistinguishable (Fig. 2B). The EP4
receptor agonist increased MUC5AC secreted protein in goblet-enriched
cells in a concentration dependent manner (p < 0.01, 33% increase at
10 nM; p < 0.001, 92% increase at 1000 nM) (Fig. 2C). The other
receptor agonists had no eﬀect on MUC5AC secreted protein in ciliated-
enriched or goblet-enriched cells.
3.4. Eﬀect of EP4 receptor agonist on phosphorylation of CREB
The EP4 receptor agonist phosphorylated CREB in both ciliated-
enriched and goblet-enriched cells (Fig. 3A and B). Phosphorylation of
CREB peaked at 30 min, and then decreased at 120 min. EP4 receptor
activation increased CREB at 30 min (p < 0.05, 51% increase com-
pared to 0 min) in ciliated-enriched cells, and increased CREB at 30 min
(p < 0.01, 121% increase compared to 0 min) and 60 min (p < 0.05,
85% increase compared to 0 min) in goblet-enriched cells. Phosphor-
ylation of CREB by EP4 receptor activation in goblet-enriched cells was
somewhat greater than in ciliated-enriched cells at 30 min.
3.5. Eﬀect of IL-13 on EP receptors mRNA expression and protein
expression
Compared to ciliated-enriched cells (grown without IL-13) a 14 day
exposure to 5 ng/mL IL-13, increased EP4 receptor mRNA expression
while EP1, EP2, and EP3 receptor mRNA were decreased (EP1 receptor
p < 0.001, 74% decrease; EP2 receptor p < 0.001, 82% decrease;
EP3 receptor p < 0.001, 95% decrease; EP4 receptor p < 0.01, 114%
increase at goblet-enriched cells) (Fig. 4A, B, C, D). The PGE2 receptor
agonists at 1000 nM for 14 days did not aﬀect receptor expression. EP4
receptor protein was increased with 14 days of IL-13 exposure
(p < 0.01, 65% increase at goblet-enriched cells) (Fig. 4E).
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Fig. 2. The eﬀect of PGE2 receptor agonist on MUC5AC secretion.
(A) EP4 receptor agonist (1000 nM) exposure for 14 days modestly increased MUC5AC secretion in ciliated-enriched cells. (B) Morphology (a, b) Haematoxylin–eosin (H&E) staining, (c,
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T. Akaba et al. Pulmonary Pharmacology & Therapeutics 48 (2018) 117–123
120
4. Discussion
We show that PGE2 stimulates mucin production via EP4 receptor
activation in both ciliated-enriched and goblet-enriched airway cul-
tures, but did not visibly change ciliated cell morphology toward a
goblet cell phenotype. Although in this study we did not evaluate if
PGE2 is a direct mucin secretagogue, we did show that mucin mRNA
and protein were increased EP4 receptor activation had a much more
pronounced eﬀect increasing MUC5AC in goblet-enriched cells asso-
ciated with a concomitant increase EP4 receptor expression on these
goblet cells.
The EP4 receptor is a G protein-coupled receptor, activating adenyl
cyclase to convert ATP into the second messenger cAMP [7,9]. In-
creased cAMP activates protein kinase A and MAPK pathways. CREB is
subsequently activated by these upstream pathways and mediates
mucin secretion stimulated by PGE2 and prostaglandin F2α [19,20].
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We found that CREB phosphorylation by EP4 receptor activation was
greater in goblet-enriched cells. An increase in phosphorylated CREB is
reported in airway biopsy specimens from subjects with asthma and is
associated with asthma severity [21]. Although the eﬀect of IL-13 on
secreted MUC5AC plateaued at 5 ng/mL, increased EP4 receptor ex-
pression and CREB phosphorylation, which is independent of the IL-13
activated JAK/STAT6 pathway may further increase MUC5AC in
goblet-enriched cells [3].
It has been reported that cAMP also acts via Epac and Epac to at-
tenuate CREB. However, in human monocytes ONO-AE1-329 (the EP4
receptor agonist used in this study) worked entirely through the cAMP-
PKA pathway and not vis Epac [12]. Our data suggests that the cAMP-
PKA-CREB pathway predominates for MUC5AC secretion in these cul-
tured human airway epithelial cells.
EP2 receptor activation at the apical side increased MUC5AC mRNA
in ciliated-enriched cells. This is consistent with reports that the EP2
receptor is mainly expressed at the apical surface of epithelial cells and
EP2 receptor activation increased intracellular cAMP [7,22]. Although
it is possible that EP2 increases secreted mucin, this is probably clini-
cally irrelevant as we found decreased EP2 receptor expression on IL-13
transformed goblet cells and no signiﬁcant eﬀect on mucin in those
cultures.
We previously reported that sPLA2 increases secreted mucin from
goblet cells through both the cyclooxygenase and the lipoxygenase
pathways [17]. It is also reported that IL-1β induced PGE2 production
in airway epithelial cells and increased MUC5AC production [14]. Al-
though Trudeau and colleagues reported that IL-13 attenuates PGE2
synthesis and PGE2 secretion in airway cells from normal and asthma
subjects [23], both the data presented in these experiments and our
previous studies showed that 14 days exposure to IL-13 increases PGE2
secretion, which is consistent with clinical reports that PGE2 in asthma
sputa is greatly increased [8,17]. PGE2 most likely increases secreted
mucin in asthma through the EP4 receptor.
Diﬀering from our results, an in vivo study showed that sub-
cutaneous injection of the EP2, EP3, and EP4 receptor agonists blocked
mucus hypersecretion induced by ovalbumin challenge in the rat nose
[24], whilst we show that EP4 receptor activation increased MUC5AC
production. It may be that in the animal study, the systemic adminis-
tration of the EP4 receptor agonist activated circulating macrophages or
monocytes inhibiting inﬂammatory cytokine release including IL-13
[7,12]. It is also possible that activation of the receptors has a diﬀerent
eﬀect in the rat than in cultured human airway cells. Clinically, in-
hibition of cyclooxygenase (the pathway necessary for prostaglandin
synthesis), can profoundly worsen asthma in so-called triad asthmatics
who are sensitive to acetyl silicic acid. Although the pathogenic me-
chanism of this type of asthma is not fully understood, it is likely to be
due in part, to imbalance in eicosanoid metabolism with increased
production of cysteinyl leukotrienes and reduced synthesis of PGE2
[25].
Although the eﬀect of EP4 receptor activation in ciliated cells is
probably not clinically signiﬁcant, EP4 receptor activation greatly in-
creased MUC5AC production in goblet cells in association with in-
creased EP4 receptor expression. This may contribute to mucus hy-
persecretion as seen in severe asthma.
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